A recent study reported that silencing PRMT6 potentiated tumor metastasis, increased migration and invasion, and was resistant to cisplatin, 5-fluorouracil, and sorafenib treatment therapy in hepatocellular carcinoma (HCC) (Figure 5). Here, PRMT6 is linked to hepatocellular carcinoma.